Your browser doesn't support javascript.
loading
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Rini, Brian I; Stenzl, Arnulf; Zdrojowy, Romauld; Kogan, Mikhail; Shkolnik, Mikhail; Oudard, Stephane; Weikert, Steffen; Bracarda, Sergio; Crabb, Simon J; Bedke, Jens; Ludwig, Joerg; Maurer, Dominik; Mendrzyk, Regina; Wagner, Claudia; Mahr, Andrea; Fritsche, Jens; Weinschenk, Toni; Walter, Steffen; Kirner, Alexandra; Singh-Jasuja, Harpreet; Reinhardt, Carsten; Eisen, Tim.
Afiliação
  • Rini BI; Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA. Electronic address: rinib2@ccf.org.
  • Stenzl A; University of Tübingen, Tübingen, Germany.
  • Zdrojowy R; Wroclaw Medical University, Wroclaw, Poland.
  • Kogan M; Rostov State Medical University of Roszdrav, Rostov-on-Don, Russia.
  • Shkolnik M; Russian Scientific Center of Radiology and Surgery Technologies, St Petersburg, Russia.
  • Oudard S; Hopital Europeen Georges Pompidou, Paris, France.
  • Weikert S; Vivantes Humboldt Clinic, Berlin, Germany.
  • Bracarda S; Ospedale San Donato, Arezzo, Italy.
  • Crabb SJ; University of Southampton, Southampton, UK.
  • Bedke J; University of Tübingen, Tübingen, Germany.
  • Ludwig J; Immatics Biotechnologies, Tübingen, Germany.
  • Maurer D; Immatics Biotechnologies, Tübingen, Germany.
  • Mendrzyk R; Immatics Biotechnologies, Tübingen, Germany.
  • Wagner C; Immatics Biotechnologies, Tübingen, Germany.
  • Mahr A; Immatics Biotechnologies, Tübingen, Germany.
  • Fritsche J; Immatics Biotechnologies, Tübingen, Germany.
  • Weinschenk T; Immatics Biotechnologies, Tübingen, Germany.
  • Walter S; Immatics Biotechnologies, Tübingen, Germany.
  • Kirner A; Immatics Biotechnologies, Tübingen, Germany.
  • Singh-Jasuja H; Immatics Biotechnologies, Tübingen, Germany.
  • Reinhardt C; Immatics Biotechnologies, Tübingen, Germany.
  • Eisen T; University of Cambridge, Cambridge, UK.
Lancet Oncol ; 17(11): 1599-1611, 2016 Nov.
Article em En | MEDLINE | ID: mdl-27720136
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirróis / Carcinoma de Células Renais / Vacinas Anticâncer / Indóis / Neoplasias Renais Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirróis / Carcinoma de Células Renais / Vacinas Anticâncer / Indóis / Neoplasias Renais Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article